The U.S. Food and Drug Administration (FDA) has approved Onapgo (apomorphine hydrochloride) injection, the first and only ...
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...
Ozzy Osbourne will come out of touring retirement and reunite with the full Black Sabbath lineup for the first time in 20 ...
Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...
Parkinson’s disease is a brain disorder that affects movement, making everyday tasks difficult for nearly one million people ...
GOTHENBURG, SE / ACCESS Newswire / February 7, 2025 /IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients. Serina Therapeutics, based ...
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...
Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for ...
The exploration of natural products and their structural analogues in neuropsychiatry has historically been a fertile area of research, driven by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback